1. Overview
1.1 About this Report
1.2 Scope of the Report
1.3 Objectives
1.4 Methodology
1.5 Executive Summary
2. Overview of Diagnostic Testing Point of Care
2.1 POCT Testing Sites
2.2 POCT Market Structure
2.3 New Directions in Clinical IVD Testing
3. POC and Rapid Testing Market Analysis: Size, Background Analysis, Growth, Share and Competitors
3.1 Global POCT Market
3.2 U.S. POCT Market
3.3 European POCT Market
3.3.1 German Point of Care Diagnostic Market
3.3.2 U.K. POCT Diagnostic Market
3.3.2.1 U.K. POC Market Statistics
3.3.2.2 U.K. Competitive Analysis
3.3.2.3 U.K. Market Access
3.3.3 French Point of Care Diagnostic Market
3.3.4 Italian POC Diagnostic Market
3.3.5 Spanish POC Diagnostic Market
3.3.6 Scandinavian Point of Care Market
3.3.7 Swedish POCT Market
3.3.8 Finland POCT Market
3.3.9 Norway POCT Market
3.3.10 Swiss POCT Market
3.3.11 Dutch Clinical Laboratory Diagnostic Market
3.3.12 Belgian Clinical Laboratory Diagnostic Market
3.3.13 Portugal Clinical Laboratory Diagnostic Market
3.3.14 Austria Clinical Laboratory Diagnostic Market
3.3.15 Greek Clinical Laboratory Diagnostic Market
3.3.16 Poland Clinical Laboratory Diagnostic Market
3.3.17 Czech Republic Clinical Laboratory Diagnostic Market
3.3.18 Turkish Point of Care Market
3.4 Asian POCT Markets
3.4.1 Japanese POCT Market
3.4.2 Indian POCT Market
3.4.3 Chinese Point of Care Market
3.5 Rest of the World POCT Market
3.5.1 Canada Point of Care Market
3.5.2 Brazil Point of Care Market
3.5.3 Australia Point of Care Market
3.6 Overview of Asian Healthcare Market
3.6.1 Singapore
3.6.2 Malaysia
3.6.3 Thailand
3.6.4 Indonesia
3.6.5 Philippines
3.6.6 South Korea
3.6.7 Taiwan
4. POCT Individual Markets
4.1 Glucose Testing
4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors
4.2.1 World Market
4.2.2 U.S. Market
4.2.3 European Market
4.2.3 Alternate Glucose Monitoring Products
4.2.4 HbA1c POCT
4.3 Blood Gas and Electrolytes
4.3.1 Whole Blood Lactate
4.4 Rapid Coagulation Tests
4.4.1 World POCT Coagulation Market
4.4.2 U.S. Coagulation Market
4.4.2 European Coagulation Market
4.5 Rapid Cardiac Markers
4.5.1 U.S. Market
4.5.2 European Market
4.6 Drugs of Abuse Screening Testing
4.6.1 Acetaminophen
4.6.2 Tricyclic Antidepressants (TCAs)
4.6.3 Other Toxic Drugs
4.6.4 Drug Testing Selectivity
4.6.5 Methaqualone and Phencyclidine (PCP)
4.6.6 Tetrahydrocannabinol
4.6.7 Drug Panels by Toxidromes
4.6.8 Alcohol Testing
4.7 Urine Strips
4.8 Pregnancy Tests
4.9 Fecal Occult Blood
4.10 Hemoglobin Testing
4.11 Miscellaneous Rapid Tests
4.11.1 Estriol
4.11.2 Fetal Fibronectin (fFN)
4.11.3 H. pylori
4.11.4 Vaginal pH and Vaginitis
4.11.5 Bladder Cancer
4.11.6 Fetal Status
4.12 Human Immunodeficiency Virus (HIV)
4.13 Cholesterol
4.14 Infectious Disease
4.14.1 C. difficile
4.14.2 Giardia
4.14.3 Salmonella and Campylobacter
4.14.4 Malaria Testing
4.14.5 Influenza Testing
4.14.6 Strep Testing
4.14.7 Chlamydia
4.14.8 Mononucleosis
4.14.9 Rubella
4.14.10 Staphylococcus Aureus
4.14.11 Hepatitis
4.14.12 Gonorrhea
4.14.13 Tuberculosis (TB)
4.14.14 Herpes Simplex Virus Type-2
4.15 Infant Jaundice
4.16 Anthrax
4.15 Rupture of Fetal Membranes (ROM)
4.16 Food Pathogens
4.17 Typhoid
5. POCT: Reagents and Equipment
5.1 Blood Glucose Monitoring
5.1.1 LifeScan
5.1.2 Roche Accu-Chek
5.1.3 Siemens
5.1.4 Cholestech
5.1.5 Medisense (Abbott)
5.1.6 International Technidyne Corporation
5.1.7 HemoCue
5.1.8 GDS Technology
5.1.9 LXN Corporation
5.1.10 Medtronic MiniMed
5.1.11 Cygnus
5.1.12 Abaxis
5.1.13 Inverness Medical Technology
5.2 Blood Gas and Electrolytes
5.2.1 Optical Sensors, Inc.
5.2.2 Roche Corporation
5.2.3 TechnoMedica
5.2.4 Siemens
5.2.5 Instrumentation Laboratory
5.2.6 Nova Biomedical
5.2.7 Radiometer
5.2.8 Abbott (i-STAT Corporation)
5.2.9 Span Diagnostics
5.2.10 Avox Systems
5.2.11 Disetronic Medical Systems
5.2.12 Nova
5.2.13 ITC
5.2.14 Osmetech
5.3 Rapid Coagulation Tests
5.3.1 POC Coagulation Instrument Description
5.3.1.1 Roche Diagnostics Corp.
5.3.1.2 Abbott (i-STAT Corp.)
5.3.1.3 International Technidyne Corp.
5.3.1.4 Medtronic Cardiac Surgery
5.3.1.5 HemoSense
5.3.1.6 Helena Point of Care
5.3.1.7 Siemens
5.3.1.8 Beckman Coulter
5.3.1.9 Pharmanetics (Cardiovascular Diagnostics)
5.3.1.10 Sienco
5.3.1.11 Accumetrics
5.3.2 Connectivity Issues
5.3.3 Cost Benefits
5.3.4 Quality Control Issues
5.3.5 Certification for POC Coagulation Devices
5.4 Rapid Cardiac Markers
5.4.1 Spectral Diagnostics
5.4.2 Biosite Diagnostics
5.4.3 Roche Diagnostics
5.4.4 First Medical
5.4.5 Ani Biotech
5.4.6 Response Biomedical
5.4.7 Dade Behring
5.4.8 SYN•X Pharma, Inc.
5.4.9 Ark Therapeutics, Ltd.
5.4.10 Abbott (i-STAT Corp.)
5.4.11 LifeSign
5.4.12 Mitsubishi Kagaku Iatron
5.5 Rapid Drugs of Abuse
5.5.1 Biosite Diagnostics (Inverness)
5.5.2 Abbott Diagnostics
5.5.3 Roche Diagnostics
5.5.4 BioScan Screening Systems, Inc.
5.5.5 American Bio Medica Corp.
5.5.6 Pharmatech Corporation
5.5.7 Worldwide Medical
5.5.8 Syva Dade Behring
5.5.9 STC Technologies, Inc.
5.5.10 DynaGen, Inc.
5.5.11 OraSure
5.5.12 LifePoint
5.5.13 Avitar, Inc.
5.5.14 Cozart Biosciences
5.5.15 Securetec
5.6 Urine Strips
5.7 Rapid Pregnancy and Fertility Tests
5.8 Fecal Occult Blood
5.8.1 Helena Laboratories
5.8.2 Biomerica
5.8.3 Beckman Coulter
5.8.4 Wampole Laboratories
5.8.5 Worldwide Medical
5.8.6 Aerscher Diagnostics
5.8.7 Enterix
5.8.8 Medix Biochemica
5.9 Hemoglobin Testing
5.9.1 Wampole Laboratories
5.9.2 HemoCue, Inc.
5.9.3 Micro Diagnostics Corporation
5.9.4 GDS Technology
5.10 Miscellaneous Rapid Tests
5.10.1 Triage C. difficile Panel
5.10.2 Ketoacids
5.10.3 Acetaminophen
5.10.4 Estriol
5.10.5 H. pylori
5.10.6 Vaginal Fluid pH and Vaginitis
5.10.7 Prostate Specific Antigen (PSA)
5.10.8 Bladder Cancer
5.10.9 Other Rapid Cancer Tests
5.10.10 Fetal Status (PROM)
5.10.11 Osteoporosis
5.11 HIV
5.12 Cholesterol
5.12.1 Cholestech
5.12.2 Lifestream Technologies, Inc.
5.12.3 Actimed Laboratories
5.12.4 StatSite Meter
5.12.5 Polymer Technology Systems
5.12.6 International Medical Innovations Inc. (IMI)
5.13 Infectious Disease
5.13.1 C. difficile
5.13.2 Giardia
5.13.3 Dengue Fever
5.13.4 Malaria Testing
5.13.5 Rapid Influenza Testing
5.13.6 Streptococcus Testing
5.13.7 Chlamydia
5.13.8 Mononucleosis
5.13.9 Rubella
5.13.10 Staphylococcus Aureus
5.13.11 Hepatitis
5.13.12 E. coli O157
5.13.13 Gonorrhea Testing
5.13.14 Smallpox
5.13.15 SARS
5.13.16 Rabies
5.13.17 Tuberculosis
5.13.18 Avian Flu
5.13.19 West Nile Virus
5.13.20 Herpes Simplex Virus Type-2
5.14 Infant Jaundice
5.15 Anthrax
5.16 Homeland Defense
5.17 BSE (Mad Cow Disease)
5.18 Tuberculosis
5.19 Typhoid
5.20 Avian flu
5.21 Food Pathogens (Salmonella, Listeria, Campylobacter)
5.22 Ruptured Fetal Membranes (ROM)
6. POCT: Growth Regulators
6.1 Moderators of Growth
6.2 Personnel Acceptance
6.3 Key People for POCT
6.4 Information Management Issues
6.4.1 Elements of Information Management for POCT: Information Processing Capabilities
6.4.2 Data Mining
6.4.3 Middleware
6.4.4 Web Portals
6.4.5 POCT-1A Standard
6.5 Key Elements for POCT
6.6 POCT and Reimbursement
6.7 Effectiveness of Clinical Outcomes
6.8 Rapid Near-Patient Testing in Hospitals
6.9 Satellite Facilities
6.10 Regionalization of Laboratory Care
6.11 Requirements for POCT
6.12 Locations of Point of Care for Patient Care
6.13 Benefits of POCT
6.14 TAT for POCT
6.15 Clinical Laboratory Improvement Amendments (CLIA)
6.16 Sexually-Transmitted Diseases in Underdeveloped Countries
7. Business Trends in the Point of Care Sector
7.1 Sector Consolidation
7.2 Diagnostic Testing Growth Trends
7.3 Acquisition, License Agreements, Internal Development and Partnerships
7.4 Product Testing Depth in POCT
7.5 Government Regulation
7.5.1 U.S. Regulation
7.5.1.1 Importing Medical Devices into the U.S.
7.5.1.2 Exporting Medical Devices from the U.S.
7.5.2 U.K. Regulation
7.5.3 E.U. Regulation
7.5.3.1 French Regulation
7.5.4 Japanese Regulation
7.5.5 Korean Regulation
7.6 Increased Market Penetration
7.7 Costs of Doing Business in Europe
7.8 Drivers of European Diagnostics Testing
7.9 European Reimbursement Practices
7.10 Cost Containment in Europe
8. Technology Platform Innovations in POCT
8.1 Sensor Systems for Diagnostic Applications
8.2 Glucose Measurements
8.3 Glucose Test Methods
8.4 Cholesterol Testing
8.5 The New Paradigm
8.6 Consolidated Workstations and Modularity
8.7 Automation and Robotics in the Clinical Laboratory
8.8 Laboratory Information Systems (LIS)
8.8.1 NOVIUS Lab
8.9 Biosensor Technology
9. Data Management and Connectivity
9.1 Wireless LANs
9.2 Connectivity Platforms
9.2.1 DataLink Data Management System
9.2.2 RALS-Plus
9.2.3 LabPortal.com
9.2.4 BD.id
9.3 Advantages of POCT Connectivity
9.3.1 Cost Benefit of POCT and IT Connectivity
10. Corporate Profiles
10.1 Abaxis, Inc.
10.2 Abbott Diagnostics
10.3 Accumetrics, Inc.
10.4 Accurex Biomedical, Pvt., Ltd.
10.5 Adeza Biomedical Corporation
10.6 Akers Biosciences
10.7 Ambri, Ltd.
10.8 American Biogenetic Sciences, Inc.
10.9 American Bio Medica Corp.
10.10 Ani Biotech
10.11 Apogent Technologies
10.12 Ark Therapeutics
10.13 ARKRAY
10.14 Atlas Genetics
10.15 Atonomics
10.16 Avitar, Inc.
10.17 Avox Systems
10.18 Axis-Shield
10.19 Siemens Corporation
10.20 Beckman Coulter
10.21 Binax Corporation
10.22 Biomerica
10.23 BioMérieux Vitek, Inc.
10.24 BioScan Screening Systems, Inc.
10.25 Biosite Diagnostics
10.26 BioStar
10.27 British Biocell Holdings
10.28 Caliper Life Sciences
10.29 Calypte Biomedical
10.30 Cardiovascular Diagnostics
10.31 Chembio Diagnostics
10.32 ChemTrak
10.33 Cholestech
10.34 Chongqing Sungene Pharmaceutical Co., Ltd.
10.35 CompuCyte Corporation
10.36 Cortech Diagnostics Ltd. (now called Kent International Holdings)
10.37 Cozart Biosciences
10.38 Cygnus Therapeutic Systems
10.39 Cytogen
10.40 Dade Behring
10.41 Daiichi Co., Ltd.
10.42 Denka Seiken Co., Ltd.
10.43 Diagnostic Chemicals, Ltd.
10.44 Enterix, Inc.
10.45 First Medical, Inc.
10.46 Focus Diagnostics, Inc.
10.47 GDS Technology
10.48 GenBio
10.49 Genzyme Diagnostics
10.50 Grant Life Sciences
10.51 Gryphus Diagnostics
10.52 Helena Laboratories
10.53 Hema Diagnostic Systems
10.54 Hemocue, Inc.
10.55 Home Access Health Corp.
10.56 i-STAT Corporation
10.57 Instrumentation Laboratory
10.58 International Medical Innovations
10.59 Inverness Medical Innovations
10.60 Immunoscience, Inc.
10.61 Johnson & Johnson
10.62 Kyowa Medex Co., Ltd.
10.63 LifeAssays
10.64 LifePoint, Inc.
10.65 LifeScan Corporation
10.66 Lifestream Technologies
10.67 LXN Corp. (Inverness Medical Technologies)
10.68 Matritech
10.69 Medical Services International, Inc.
10.70 MediSense
10.71 Medisys
10.72 Medix Biochemica
10.73 MedMira Laboratories
10.74 Meretek Corporation
10.75 Meridian Bioscience
10.76 MiniMed
10.77 Mitsubishi Chemical USA, Inc.
10.78 Mitsubishi Kagaku Iatron
10.79 Nanogen
10.80 New Horizons Diagnostics
10.81 Nova Biomedical
10.82 Väsamed, Inc.
10.83 OraSure
10.84 Orgenics
10.85 Orion Diagnostica
10.86 PanBio, Ltd.
10.87 PharmaNetics, Inc.
10.88 Phamatech, Inc.
10.89 Royal Philips Electronics
10.90 Polymedco
10.91 Polymer Technology Systems
10.92 Princeton BioMeditech Corporation
10.93 Quest Diagnostics
10.94 Quidel
10.95 Radiometer
10.96 Response Biomedical Corp.
10.97 Roche Diagnostics
10.98 StatSure Diagnostic Systems
10.99 Savyon Diagnostics
10.100 Selfcare, Inc.
10.101 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)
10.102 Shionogi & Co., Ltd.
10.103 SpectRx, Inc.
10.104 Spectral Diagnostics
10.105 STC Technologies
10.106 Strategic Diagnostics
10.107 Sun Biomedical Laboratories
10.108 Sybron International Corporation
10.109 TCPI
10.110 Therasense, Inc.
10.111 Thermo Biostar
10.112 Thoratec/International Technidyne Corp.
10.113 Transmedica
10.114 Trinity Biotech
10.115 Venkateshwara Hatcheries Pvt., Ltd.
10.116 Wampole Laboratories
10.117 Worldwide Medical Corporation
11. POCT Sector Trends and Forecasts
11.1 Home Care Analysis as Part of Near-Patient Testing
11.2 Non-Traditional Collection for POCT
11.3 New Systems for Critical Care and Near-Patient Testing
11.4 Utility of Near-Patient Testing in Critical Care Settings
11.5 Physician’s Office Market
11.6 Information Management Advances
11.7 Test-Ordering Patterns and Demand for POCT
11.8 Demand for Emergency Department Services
11.9 Move Away From Central Laboratory
11.10 Healthcare Cost Controls
11.11 M&A in POCT
11.12 Competition for Services
11.13 Drivers of POCT
11.14 Confluence of New Technology
11.15 Difficulties of Design for POC Products
11.16 European Hospital Structure
11.17 The Biggest New Opportunities in Point of Care Testing
12. Corporate Directory
LIST OF FIGURES
Figure 3.1: Worldwide Distribution of IVD Testing in 2006
Figure 3.2: Global Point of Care Revenues, 1998 - 2008
Figure 3.3: Global Point of Care Testing Share of Total In Vitro Diagnostic Testing Market
Figure 4.1 Number of HbA1c Tests Performed Globally as POCT (in Millions)
Figure 6.1: Annual Rate of Emergency Room Visits By Primary Expected Source of Payment: U.S., 2004
INDEX OF TABLES
Table 2.1: POC Testing
Table 3.1: Number of ER Visits in U.S. Hospitals, 1997-2004
Table 3.2: Number of Point of Care Tests in U.S., 2000-2012
Table 3.3: Global Clinical Laboratory Market Sales, 1998-2010
Table 3.4: The Overall In Vitro Diagnostic Testing Market Worldwide in 2006
Table 3.5: Worldwide Distribution of IVD Testing in 2006
Table 3.6: Top Twelve Country IVD Testing Markets, 2005
Table 3.7: Fifteen Largest Diagnostic Companies Worldwide, 2005
Table 3.8: Global Point of Care Revenues, 2000-2012
Table 3.9: Worldwide POCT Market Size by Geographic Location, 2000 - 2012
Table 3.10: Worldwide Distribution of POCT, 2007
Table 3.11: Worldwide POCT by Performance Location, 2007
Table 3.12: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
Table 3.13: U.S. Clinical Laboratory Testing Market, 2003-2012
Table 3.14: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location of Analysis, 2006
Table 3.15: U.S. POCT Market, 2000-2012
Table 3.16: U.S. POCT by Performance Location, 2007
Table 3.17: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2005
Table 3.18: European Clinical Laboratory Testing IVD Reagents and Instruments Market ($), 2000-2012
Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments Market (€), 2000-2012
Table 3.20: European Clinical Laboratory Testing Diagnostics by Country Market Estimates, 2006
Table 3.21: European Rapid Point of Care Testing by Country Market Estimates, 2006
Table 3.22: Regional Comparison of Healthcare Spending for IVD for Eastern Europe
Table 3.23: European POCT Market, 2000-2012
Table 3.24: Top Twelve Country IVD and POC Testing Markets, 2005
Table 3.25: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012
Table 3.26: German POCT Diagnostics Products Market Sales, 2003-2012
Table 3.27: German Clinical Diagnostic Rapid Test Market Segments, 2006
Table 3.28: U.K. Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.29: U.K. POCT Diagnostics Products Market Sales, 2006-2012
Table 3.30: U.K. Clinical Diagnostic Rapid Test Market Segments, 2006
Table 3.31: Major U.K. IVD Manufacturers
Table 3.32: U.S. IVD Manufacturers Doing Business in the U.K.
Table 3.33: Other European Companies that Manufacture IVD Products in the U.K.
Table 3.34: French Clinical IVD Testing Diagnostics Products Market Sales, 2003-2012
Table 3.35: French POC Diagnostics Products Market Sales, 2005-2012
Table 3.36: French Clinical Diagnostic Rapid Test Market Segments, 2006
Table 3.37: Italian Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.38: Italian POC Diagnostics Products Market Sales, 2005-2012
Table 3.39: Italian Clinical Diagnostic Rapid Test Market Segments, 2006
Table 3.40: Spanish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.41: Spanish Clinical Diagnostic Rapid Test Market Segments, 2006
Table 3.42: Spanish POC Diagnostics Products Market Sales, 2005-2012
Table 3.43: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012
Table 3.44: Swedish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.45: Swedish POC Diagnostics Products Market Sales, 2005-2012
Table 3.46: Finnish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.47: Finnish POC Diagnostics Products Market Sales, 2005-2012
Table 3.48: Norwegian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.49: Norwegian POC Diagnostics Products Market Sales, 2005-2012
Table 3.50: Swiss Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.51: Swiss POCT Diagnostics Products Market Sales, 2005-2012
Table 3.52: Dutch Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.53: Dutch POC Diagnostics Products Market Sales, 2005-2012
Table 3.54: Belgium Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.55: Belgium POCT Diagnostics Products Market Sales, 2005-2012
Table 3.56: Portuguese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.57: Portuguese POCT Diagnostics Products Market Sales, 2005-2012
Table 3.58: Austrian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.59: Austrian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.60: Greek Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.61: Greek POCT Diagnostics Products Market Sales, 2005-2012
Table 3.62: Polish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.63: Polish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.64: Czech Clinical Laboratory Diagnostics Products Market Sales, 2004-2012
Table 3.65: Czech POCT Diagnostics Products Market Sales, 2005-2012
Table 3.66: Turkish POCT Market, 2000-2012
Table 3.67: Japan Point of Care Testing Market, 2000-2012
Table 3.68: Japanese Population and Aging Demographics Forecast, 2000-2050
Table 3.69: Indian IVD Market for Instruments and Reagents, 2004-2012
Table 3.70: Number of Automated Clinical Labs in India, 2004-2012
Table 3.71: Indian IVD Market, 2006
Table 3.72: Indian Point of Care Diagnostics Products Market Sales, 2000-2008
Table 3.73: Chinese IVD Market, 2006-2012
Table 3.74: Number of Automated Clinical Labs in China, 2004-2012
Table 3.75: Chinese IVD Market, 2006
Table 3.76: Chinese Point of Care Diagnostics Products Market Sales, 2000-2012
Table 3.77: The Rest of the World POCT Market, 2000-2012
Table 3.78: Canadian POCT Market, 2000-2012
Table 3.79: Brazilian POCT Market, 2000-2012
Table 3.80: Australian POCT Market, 2000-2012
Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers
Table 4.2: The Global Population of Persons with Diabetes, 1995 and 2025
Table 4.3: The Glucose Testing Market for POCT Worldwide, 2001-2012
Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012
Table 4.5: Manufacturer Market Share U.S. POCT Market, 2007
Table 4.6: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment
Table 4.7: The HbA1c Testing Market for POCT Worldwide, 2006-2012
Table 4.8: The Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012
Table 4.9: The Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012
Table 4.10: Location Market Share of Critical Care Blood Gas Testing
Table 4.11: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2005
Table 4.12: The Coagulation Testing Market for POCT Worldwide, 2006-2012
Table 4.13: The Hand-held Coagulation Testing Market for POCT Worldwide, 2006-2012
Table 4.14: The Coagulation Market for POCT in the U.S., 2001-2012
Table 4.15: The POC Prothrombin Market for POCT in the U.S., 2000-2007
Table 4.16: The Cardiac Marker Market for POCT in the U.S., 2001-2012
Table 4.17: The Cardiac Marker Market for POCT Worldwide, 2001-2012
Table 4.18: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2005
Table 4.19: The Cardiac Marker Market for POCT in Europe, 2001-2011
Table 4.20: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2012
Table 4.21: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2012
Table 4.22: Drug Testing Needs Tier 1 for Rapid Serum Point of Care Testing in the Emergency Department
Table 4.23: Stat Urine Testing Drug Recommendations
Table 4.24: Device Specifications for POC Breath Alcohol Analysis
Table 4.25: Global Point of Care Urine Test Strip Testing Market, 2001-2007
Table 4.26: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012
Table 4.27: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011
Table 4.28: U.S. Point of Care Urine Test Strip Testing Market Share
Table 4.29: Medicare Fee Schedule for Urine Chemistry Testing
Table 4.30: Pregnancy Testing Market for POCT Worldwide, 2006-2012
Table 4.31: U.S. Point of Care Pregnancy Testing Market, 2001-2012
Table 4.32: International Point of Care Pregnancy Testing Markets, 2001-2007
Table 4.33: U.S. Market Share for Rapid Point of Care Pregnancy Tests
Table 4.34: Hemoglobin Testing Market for POCT Worldwide, 2006-2012
Table 4.35: Worldwide POCT Market for HIV, 2001-2012
Table 4.36: U.S. POCT Market for HIV, 2001-2012
Table 4.37: Countries with the Highest Prevalence of HIV/AIDS
Table 4.38: FDA-Approved Rapid HIV Antibody Screening Tests
Table 4.39: OraSure OraQuick Rapid HIV Test Revenues, 2005
Table 4.40: The Cholesterol Testing Market for POCT Worldwide, 2006-2012
Table 4.41: The Infectious Disease Testing Market for POCT Worldwide, 2006-2012
Table 4.42: Salmonella Testing Market, 2002-2007
Table 4.43: Worldwide Point of Care Influenza Testing Market, 2002-2007
Table 4.44: U.S. Point of Care Influenza Testing Market, 2002-2007
Table 4.45: International Point of Care Influenza Testing Markets, 2002-2007
Table 4.46: U.S. Market for Rapid Point of Care Influenza Tests, 2005
Table 4.47: Worldwide Point of Care Strep A Testing Market, 2002-2007
Table 4.48: U.S. Point of Care Strep A Testing Market, 2002-2007
Table 4.49: International Point of Care Strep A Testing Markets, 2002-2007
Table 4.50: U.S. Market for Rapid Point of Care for Group A Strep Tests
Table 4.51: Global Market for Chlamydia Diagnostic Testing, 2000-2009
Table 4.52: U.S. Market for Chlamydia Diagnostic Testing, 2000-2009
Table 4.53: Global Market for Gonorrhea Diagnostic Testing, 2000-2009
Table 4.54: Global Market for TB Diagnostic Testing, 2000-2008
Table 4.55: U.S. Anthrax Test Market
Table 5.1: Drug Test Sensitivity Cut-Off Levels Established as Standard by NIDA, WHO and SAMHSA for Drugs of Abuse
Table 5.2: Major Competitors in the Drugs of Abuse Testing Market Segment
Table 5.3: Major Competitors in the Drugs of Abuse Oral Testing Market Segment
Table 5.4: Major Competitors in the Drugs of Abuse Urine Testing Market Segment
Table 5.5: Major Competitors in the Drugs of Abuse Saliva Testing Market Segment
Table 5.6 Siemens Urinalysis Near-patient Devices
Table 5.7: ColoCARE Fecal Occult Blood Test
Table 5.8: Type of Hepatitis Test: Lateral Flow
Table 5.9: Flow-Through
Table 5.10: Agglutination
Table 5.11: Immunoblot
Table 5.12: AmniSure
Table 6.1: Access Points
Table 6.2: Desktop Adapters—One Computer
Table 6.3: Desktop Adapters—Four Computers
Table 6.4: PCMCIA Adapters
Table 6.5: POCT1-Compliant Connectivity Point of Care Instruments
Table 6.6: POCT Clinical Outcomes in Diabetic Ketoacidosis
Table 6.7: POCT Clinical Outcomes in Arterial Blood Gas Measurements
Table 6.8: POCT in Three Hospitals. Cost Analysis with Labor Included
Table 6.9: Cost Analysis for Glucose Testing: POCT vs. Central Lab
Table 6.10: Financial Comparison for Moderate and Waived CLIA Labs
Table 7.1 Key Changes in IVD Business Structure
Table 7.2 Business Trends in Point of Care Testing
Table 7.3 Key Players Bring Business Developments to Point of Care Diagnostic Testing
Table 8.1: Normal Glucose Values—Fasting State
Table 9.1: Applications for Wireless LAN Technology
Table 9.2: Wireless LAN Technology Companies
Table 9.3: Customized Reports Must Support CAP and JCAHO Requirements
Table 9.4 RALS-Plus Point of Care Market Share
Table 9.5: Applications of RALS Connectivity with POCT Devices
Table 10.1: Products Marketed by Abbott in the Diagnostic Market
Table 10.2: Quidel Product Sales Distribution and Sales, 2006
Table 11.1: Improvements in Achieving ED Operational Efficiency Using POCT
Table 11.2: Test Menu and TAT for ED
Table 11.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED
Table 11.4: Key Areas and Metrics That Hospitals Measure To Assess Efficiency of ED
Table 11.5: Estimates of Patient Costs by DRG
